Active Biotech AB Interim report January - March 2010

(Thomson Reuters ONE) -



·           Laquinimod ? Teva extends its marketing and distribution rights for
laquinimod

·           TASQ ? preparations for Phase III trials under way

·           ANYARA ? exploratory combination data presented

·           57-57 ? exploratory clinical trial in progress

·           ISI ? project proceeding according to plan

·           RhuDex((TM) )? preclinical studies in progress

·           Net sales of SEK 2.8 M (2.2)

·           Operating loss of SEK 51.0 M (loss: 63.7)

·           Loss after tax of SEK 53.5 M (loss: 62.2)

·           Loss per share for the period amounted to SEK 0.83 (loss: 1.21)

·           After the end of the period a directed share issue raised
approximately SEK 149 M for the company


For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95

Göran Forsberg
VP Investor Relations & Business Development
Tel: +46 (0)46-19 11 54

Hans
Kolam
CFO
Tel: +46 (0)46-19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

This report is also available at www.activebiotech.com



[HUG#1406538]





Active Biotech Interim report January-March 2010: http://hugin.info/1002/R/1406538/359991.pdf

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 22.04.2010 - 08:30 Uhr
Sprache: Deutsch
News-ID 19491
Anzahl Zeichen: 0

contact information:
Town:

LUND

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 187 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Active Biotech AB Interim report January - March 2010"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech